

1 **SENATE FLOOR VERSION**

2 April 1, 2019

3 ENGROSSED HOUSE
4 BILL NO. 2638

5 By: Munson, Echols, Bush,
6 Fetgatter, Frix, Wallace,
7 Kannady, Dunnington,
8 Dollens, McEntire, Mize,
9 Bennett, Caldwell (Trey),
10 Moore, Roberts (Dustin),
11 Blancett, Miller, Sneed,
12 Perryman, Hill, Humphrey,
13 Lawson and **West (Josh)** of
14 the House

15 and

16 Rader, **Smalley, Young,**
17 **Simpson, Daniels, Kidd,**
18 **Rosino and Hicks** of the
19 Senate

20 An Act relating to insurance; providing for step
21 therapy reform; defining terms; directing providers
22 to establish guidelines; providing for exceptions;
23 providing for response to requests; directing
24 Insurance Department to promulgate rules; providing
for codification; and providing an effective date.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 1-2610 of Title 63, unless there
is created a duplication in numbering, reads as follows:

A. As used in this section:

1 1. "Clinical practice guidelines" means a systematically
2 developed statement to assist decision-making by health care
3 providers and patients about appropriate health care or specific
4 clinical circumstances and conditions;

5 2. "Clinical review criteria" means written screening
6 procedures, decision abstracts, clinical protocols and practice
7 guidelines used by an insurer, health plan or utilization review
8 organization to determine the medical necessity and appropriateness
9 of health care services;

10 3. "Health insurance plan" means any individual or group health
11 insurance policy, medical service plan, contract, hospital service
12 corporation contract, hospital and medical service corporation
13 contract, fraternal benefit society, health maintenance
14 organization, municipal group-funded pool, the Oklahoma Medicaid
15 program and state health care benefits plan that provides medical,
16 surgical or hospital expense coverage. For purposes of this
17 section, "health insurance plan" also includes any utilization
18 review organization that contracts with a health insurance plan
19 provider;

20 4. "Medical necessity" means that, under the applicable
21 standard of care, a health service or supply is appropriate to
22 improve or preserve health, life or function to slow the
23 deterioration of health, life or function or for the early
24

1 screening, prevention, evaluation, diagnosis or treatment of a
2 disease, condition, illness or injury;

3 5. "Step therapy protocol" means a protocol or program that
4 establishes a specific sequence in which prescription drugs for a
5 specified medical condition that are medically appropriate for a
6 particular patient are covered by a health insurance plan;

7 6. "Step therapy exception" means a process by which a step
8 therapy protocol is overridden in favor of immediate coverage of the
9 health care provider's selected prescription drug; and

10 7. "Utilization review organization" means an entity that
11 conducts utilization review, not including a health insurance plan
12 provider performing utilization review for the provider's own health
13 insurance plan.

14 B. For any health insurance plan that is delivered, issued for
15 delivery, amended or renewed on or after January 1, 2020, that
16 utilizes a step therapy protocol, the health insurance plan provider
17 shall establish guidelines governing the use of the step therapy
18 protocol using clinical review criteria based on clinical practice
19 guidelines, subject to the following requirements:

20 1. Clinical review criteria used to establish a step therapy
21 protocol shall be based on clinical practice guidelines that:

22 a. recommend prescription drugs be taken in the specific
23 sequence required by the step therapy protocol,

24

1 b. are developed and endorsed by a multidisciplinary
2 panel of experts that manages conflicts of interest
3 among the panel's members of the writing and review
4 groups by:

5 (1) requiring members to disclose any potential
6 conflicts of interest with entities, including
7 health insurance plan providers and
8 pharmaceutical manufacturers, and to recuse
9 themselves from voting on any matter in which a
10 member has such a conflict,

11 (2) using a methodologist to work with writing groups
12 to provide objectivity in data analysis and
13 evidence ranking by preparing evidence tables and
14 facilitating consensus, and

15 (3) offering opportunities for public review and
16 comment,

17 c. are based on high-quality studies, research and
18 medical practice,

19 d. are created by an explicit and transparent process
20 that:

21 (1) minimizes biases and conflicts of interest,

22 (2) explains the relationship between treatment
23 options and outcomes,

24

1 (3) rates the quality of evidence supporting
2 recommendations, and

3 (4) considers relevant patient subgroups and
4 preferences, and

5 e. are continually updated through review of new
6 evidence, research and newly developed treatments;

7 2. In the absence of clinical guidelines that meet the
8 requirements of subparagraph b of paragraph 1 of this subsection,
9 peer-reviewed publications may be substituted;

10 3. When establishing clinical review criteria for a step
11 therapy protocol, a utilization review agent shall also account for
12 the needs of atypical patient populations and diagnoses; and

13 4. Nothing in this subsection shall be construed to require a
14 health insurance plan provider to establish a new entity to develop
15 clinical review criteria used for a step therapy protocol.

16 C. 1. For any health insurance plan that is delivered, issued
17 for delivery, amended or renewed on or after January 1, 2020, that
18 restricts coverage of a prescription drug for the treatment of any
19 medical condition pursuant to a step therapy protocol, the health
20 insurance plan provider shall provide to the prescribing health care
21 provider and patient access to a clear, convenient and readily
22 accessible process to request a step therapy exception. Any health
23 insurance plan provider that utilizes a step therapy protocol shall

24

1 make such process to request a step therapy exception accessible on
2 the health insurance plan provider's website.

3 2. A health insurance plan shall grant a requested step therapy
4 exemption if:

5 a. the required prescription drug is contraindicated or
6 will likely cause an adverse reaction by or physical
7 or mental harm to the patient,

8 b. the required prescription drug is expected to be
9 ineffective based on the known clinical
10 characteristics of the patient and the known
11 characteristics of the prescription drug,

12 c. the patient has tried the required prescription drug
13 while under the patient's current or a previous health
14 insurance plan or another prescription drug in the
15 same pharmacologic class or with the same mechanism of
16 action and such prescription drug was discontinued due
17 to lack of efficacy or effectiveness, diminished
18 effect or an adverse event,

19 d. the required prescription drug is not in the best
20 interest of the patient based on medical necessity, or

21 e. the patient is stable on a prescription drug selected
22 by the patient's health care provider for the medical
23 condition under consideration while on the patient's
24 current or a previous health insurance plan.

1 3. A health insurance plan provider shall permit a patient to
2 appeal any decision rendered on a request for a step therapy
3 exception.

4 D. A health insurance plan provider shall respond to a request
5 for a step therapy exception, or any appeal therefor, within
6 seventy-two (72) hours of receipt of the request or appeal. If a
7 patient's prescribing health care provider indicates that exigent
8 circumstances exist, the health insurance plan provider shall
9 respond to such a request or appeal within twenty-four (24) hours of
10 receipt of the request or appeal. If the health insurance plan
11 provider fails to respond within the required time, the step therapy
12 exception or appeal shall be deemed granted. Upon granting a step
13 therapy exception, the health insurance plan provider shall
14 authorize coverage for and dispensation of the prescription drug
15 prescribed by the patient's health care provider.

16 E. This section shall not be construed to prevent a health care
17 provider from prescribing a prescription drug that is determined to
18 be medically appropriate.

19 F. The Insurance Department and the Oklahoma Health Care
20 Authority shall adopt rules and regulations as may be necessary to
21 implement and administer this section prior to January 1, 2020.

22 SECTION 2. This act shall become effective November 1, 2019.

23 COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
24 April 1, 2019 - DO PASS